Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Cancer Cachexia Market Outlook

The global cancer cachexia market size attained a value of USD 2.32 billion in 2023 driven by continuous clinical trials in oncology, expanding mindfulness among individuals and healthcare experts, presence of an enormous pool of undiscovered patients, quick urbanisation, and expanding government support for healthcare. The market is anticipated to grow at a CAGR of 4.7% during the forecast period of 2024-2032 to attain a value of USD 3.51 billion by 2032.

Global Cancer Cachexia Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Cancer Cachexia Market Likely to be Driven by Rising Number of Cachexia Cases and Advancements in Treatment Systems

The global market for cancer cachexia is expected to be driven by rising instances of cachexia and developments in modern treatment systems. North America, Europe and Japan are expected to be key markets. Cases of cachexia are growing and presently, the condition affects nearly 1 percent of all patients. Recent years have witnessed increased understanding of the multifarious nature of cachexia, in particular, the function of inflammatory mediators and anabolic and catabolic imbalances. While many treatment methodologies have not been able to clear phase III clinical trials despite initial promise, the ghrelin receptor agonist anamorelin has delivered initial results.

Cachexia is a serious outcome of a variety of chronic conditions, and associated with a poor quality of life. In last-stage chronic heart failure, the occurrence of cachexia ranges from 5–15 percent; in cases of advanced cancer, the incidence of cachexia lies between 50–80 percent. Many people with chronic renal disease, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis develop cachexia as they near the end of their lives. Cachectic syndrome is a key source of morbidity and mortality in cancer patients. Cancer cachexia has also been linked to decreased chemotherapeutic efficacy, increased adverse effects, and discontinuation of treatment. Progressive cachexia signals poor prognosis with a shorter survival time, and explains close to 20 percent of all cancer deaths. If there is weight loss of 10 percent or more within a period of 6 months, it may indicate presence of cachexia. There is a direct relation between survival of cancer patients and rate and amount of weight loss.

Cachectic syndrome is described to have three stages - precachexia, cachexia, and refractory cachexia. In the precachectic stage, indications such as such as weight loss (less than 5 percent), anorexia, and impaired glucose tolerance appear. Advancement to cachexia depends on several factors including systemic inflammation, type and stage of cancer, low food intake, and response to treatment. In refractory cachexia, active weight loss management is rendered almost impossible due to active catabolism or presence of cachectic factors. Patients experiencing acute muscle wasting are not likely to gain from treatments aimed at achieving   lean tissue and function. In this phase, therapy seeks to mitigate symptoms and reduce distress rather than prolong life.

Combination Therapies Involving Novel Medicinal Agents Show Promise; New Drugs Expected to Stimulate Market

At present, cancer cachexia is incurable. Current therapies for cachexia entail a multidisciplinary approach; combination therapy including diet adjustments and exercise (where possible) has been integrated with new medicinal agents such as Megestrol acetate, medroxyprogesterone, ghrelin, and omega-3-fatty acid, among others. These treatments have been reported to yield better survival rates and quality of life. Advancements in treatment systems and promise shown by under-trial drugs are expected to boost the market.

In 2021, Helsinn, a Swiss pharmaceutical group engaged in the production of high-quality cancer care and rare disease products, announced the first launch of Adlumizo (anamorelin) to treat cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer in Japan, through Ono Pharmaceutical, its partner firm. Adlumizo (anamorelin), approved by the Japanese Health Authorities, has been shown to be effective in increasing body weight, muscle mass, and appetite in cancer cachexia patients.

AV-380 by AVEO is first-in-class, potent, humanized inhibitory IgG1 antibody targeting growth differentiation factor 15 (GDF15). Preclinical data suggest that inhibition of GDF15 leads to a switch from catabolism to anabolism, which indicates that GDF15 inhibition with AV-380 may reverse the effects of cachexia. As of 2023, AVEO Oncology completed enrolment in its phase I trial in Cachexia (In volunteers) in USA (Parenteral) (NCT04815551), and planned to commence a phase Ib trial in Cancer in mid-2022.

Global Cancer Cachexia Market Segmentation

Global Cancer Cachexia Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By therapeutics, the market is divided into:

  • Progestogens
  • Corticosteroids
  • Combination Therapy
  • Others

By mechanism of action, the market is classified into:

  • Appetite Stimulators
  • Weight Loss Stabilizers

By distribution channel, the market is segmented into:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By region, the market is classified into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Cancer Cachexia Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Industry Players in the Global Cancer Cachexia Market

The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Merck & Co., Inc.
  • Aphios Corporation
  • Helsinn Healthcare SA
  • AVEO Pharmaceuticals, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapeutics
  • Mechanism of Action
  • Distribution Channel
  • Region
Breakup by Therapeutics
  • Progestogens
  • Corticosteroids
  • Combination Therapies
  • Cannabinoids
  • Nonsteroidal anti-inflammatory drugs
  • Anabolic agents
  • Immunomodulatory agents
  • Ghrelin receptor agonists
  • Others
Breakup by Mechanism of Action
  • Appetite Stimulators
  • Weight Loss Stabilizers
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Aeterna Zentaris Inc.
  • Aphios Corporation
  • Atara Biotherapeutics Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GTx, Inc.
  • Helsinn Group
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • XBiotech Inc.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

In 2023, the global market of Cancer Cachexia attained a value of USD 2.32 billion.

The market is anticipated to grow at a CAGR of 4.7% during the forecast period of 2024-2032 to reach a value of USD 3.51 billion by 2032.

The major drivers of the market include the neglected requirement for the therapy of cancer cachexia in creating economies, continuous clinical trials in oncology, expanding mindfulness among individuals and healthcare experts, presence of an enormous pool of undiscovered patients, quick urbanisation, and expanding government support for healthcare.

The rising instances of cachexia and developments in modern treatment systems are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

On the basis of therapeutics, the market is divided into progestogens, corticosteroids, and combination therapy, among others.

Based on mechanism of action, the market is divided into appetite stimulators and weight loss stabilisers.

The several distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy.

The major players in the industry are Merck & Co., Inc., Aphios Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc., among others.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124